• A Wrotek and T Jackowska.
• Department of Pediatrics, Medical Center of Postgraduate Education, 99-103 Marymoncka St., 01-813 Warsaw, Poland.
• Respir Physiol Neurobiol. 2015 Apr 1; 209: 120-3.

AbstractAlthough pneumonia is one of the most important health problems in children, there is still no widely accepted disease severity score, the data on the correlation between the conventional inflammatory markers or chest X-ray and the disease severity remain disputable, and thus, there is an urgent need for a new pneumonia biomarker. The soluble urokinase plasminogen activator (suPAR) is a soluble form of the urokinase plasminogen activator that plays an important role in the innate host defense in the pulmonary tissue. suPAR levels have been associated with a general activation of the immune system rather than with a particular etiological factor. suPAR has a high prognostic value in critically ill patients, especially with sepsis, but there is a growing number of studies focusing on suPAR in respiratory diseases. The aim of this review is to summarize the knowledge on the role of the suPAR/uPAR in lung pathology and its possible use in pneumonia in children. Copyright © 2015 Elsevier B.V. All rights reserved.

17 keywords...

hide…